A new research agenda to accelerate malaria elimination and eradication

November 30, 2017, Barcelona Institute for Global Health (ISGlobal)
P. falciparum merozoites. Glasswork by L. Jerram. Credit: Malaria glasswork by Luke Jerram. Graphic Design by Rachel Papernick

More than 180 scientists, malaria programme leaders and policy makers from around the world have come together through a consultative process to update the research agenda for malaria elimination and eradication, first published in 2011. The outcome is a series of seven 'malERA Refresh' (malaria eradication research agenda) papers that have been published as a special collection in PLOS Medicine. The aim of this exercise, coordinated by the Malaria Eradication Scientific Alliance (MESA) with headquarters at the Barcelona Institute for Global Health (ISGlobal), was to define a forward-looking research and development agenda that will accelerate progress towards malaria elimination and global eradication.

A world free of malaria would present enormous benefits in terms of health, equity and economy. The WHO has set ambitious goals for reducing the burden of malaria, and 21 countries have been identified as having the potential to eliminate local transmission of malaria by 2020. However, there is no easy path to achieving a malaria-free world and there is a real need for innovation. MalERA Refresh sets out a research agenda to meet the challenges, achieve these goals and, in the long-term eradicate it globally.

"The value of malERA Refresh is that it focuses on problems that need to be solved, not only the technologies that could be developed" states MESA chair Dr. Regina Rabinovich (ISGlobal and Harvard T.H. Chan School of Public Health). "Transforming the mindset from implementation to problem solving is an essential task for the next generation of scientists and program implementers," she adds.

The key messages highlighted in the introductory paper of the malERA Refresh collection can be summarized as follows:

  • Since 2011 significant progress has been made in R&D, including support for large-scale testing of the first approved vaccine (RTS,S), non-pyrethroid insecticides in the pipeline, new genetic technologies to block parasite transmission by mosquitoes, and identification of markers of drug resistant parasites.
  • This progress however has been matched with significant challenges, such as the expansion of insecticide and drug resistance, knowledge gaps particularly when working in low disease transmission settings, and tools to prevent disease reintroduction. Concerning Plasmodium vivax malaria, the most common malaria outside Africa, more is known about its transmission biology and epidemiology but we still lack tools to tackle it. In addition, the continuous evolution of malaria parasites and vectors brings new challenges. An example is the reported rise of Plasmodium knowlesi infections in South-East Asia, as well as changes in mosquito biting and resting habits.
  • Solutions to these problems require three types of innovation: 1) iterative innovation (for example, new medicines); 2) transformative innovation of tools and strategies to reduce or halt parasite transmission (for example, gene drive technologies); and 3) integrated approaches tailored to local contexts and local variations in disease transmission dynamics.

To update the agenda, six panels with over 180 experts from different disciplines and countries engaged in a collaborative process to address progress made and main challenges in the following areas: basic science and technologies; insecticide and drug resistance; characterising the reservoir and measuring transmission; diagnostics, drugs, vaccines and vector control; combination interventions and modelling; and health systems and policy research.

"A critical recognition of the malERA Refresh is that eradication efforts perturb the ecological balance of . This changing landscape requires ongoing research to understand the impact of this perturbation, and the resulting need to change tactics. This iterative process is the core of the malERA Refresh effort," says Professor Dyann Wirth (Harvard T.H. Chan School of Public Health).

Each panel was guided by a chair and co-chair(s) who are renowned experts in their respective fields. The whole process was overseen by a Leadership Group composed of Drs. Regina Rabinovich (ISGlobal and Harvard T.H. Chan School of Public Health), Pedro Alonso (WHO Global Malaria Programme), Marcel Tanner (Swiss Tropical and Public Health Institute) and Dyann Wirth (Harvard T.H. Chan School of Public Health).

Dr. Rabinovich warns that in order to pursue the opportunities proposed in the agenda, a diverse landscape of funders is needed, as well as "a continuous monitoring of research, its impact and the emergence of new challenges to keep the community on course."

For Professor Marcel Tanner (Swiss TPH), "MalERA-refresh will give new momentum to science in the public and private sectors and particularly the key R&D efforts that will make elimination possible."

The malERA Refresh collection is considered a complement to the WHO 'Global Technical Strategy for Malaria' (GTS) and the Roll Back Malaria 'Action and Investment to defeat Malaria' (AIM). Pedro Alonso, Director of the WHO Global Malaria Programme, underlined the importance of the updated agenda as a key pathfinder for the Global Observatory on Health R&D and added: "Robust research is critical for the WHO to build evidence-based policies and guidelines."

Explore further: Should we commit to eradicate malaria worldwide?

More information: collections.plos.org/malera-refresh

Rabinovich RN, Drakeley C, Djimde AA, Hall BF, Hay SI, Hemingway J, et al. (2017) malERA: An updated research agenda for malaria elimination and eradication. PLoS Med 14(11): e1002456. doi.org/10.1371/journal.pmed.1002456

Related Stories

Should we commit to eradicate malaria worldwide?

March 3, 2017
For Bruno Moonen, Deputy Director for malaria at the Global Health Program, eradication is the only equitable and sustainable solution.

Superbug's spread to Vietnam threatens malaria control

September 21, 2017
A highly drug resistant malaria 'superbug' from western Cambodia is now present in southern Vietnam, leading to alarming failure rates for dihydroartemisinin (DHA)-piperaquine—Vietnam's national first-line malaria treatment, ...

Eliminating malaria has longlasting benefits for many countries

February 21, 2013
Many nations battling malaria face an economic dilemma: spend money indefinitely to control malaria transmission or commit additional resources to eliminate transmission completely.

Hormone-disrupting compound could provide new approach to malaria control

December 15, 2016
A chemical that disrupts biological processes in female mosquitoes may be just as effective as insecticides in reducing the spread of malaria, according to a new study from Harvard T.H. Chan School of Public Health.

Recommended for you

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Flu shot only 36 percent effective, making bad year worse (Update)

February 15, 2018
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses.

IFN-mediated immunity to influenza A virus infection influenced by RIPK3 protein

February 15, 2018
Each year, influenza kills half a million people globally with the elderly and very young most often the victims. In fact, the Centers for Disease Control and Prevention reported 37 children have died in the United States ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.